Ailani J, Lalla A, Halker Singh RB, Holle-Lee D, et al. Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies. Cephalalgia 2024;44:3331024241299377.
PMID: 39558612